Yuhan (000100.KS)

Executive Summary

Yuhan Corporation, founded in 1926, is a leading South Korean pharmaceutical company with a diversified portfolio spanning ethical pharmaceuticals, consumer healthcare, and animal health. Backed by strong R&D capabilities in small molecule chemistry, biologics, and drug delivery, the company employs a strategic open innovation model to develop innovative therapies for oncology, metabolic diseases, and respiratory conditions. With a market capitalization exceeding $7.3 billion and over 26 commercial products, Yuhan is one of Asia's most established research-driven pharmaceutical enterprises, generating steady revenue from its marketed drugs while advancing a pipeline of novel candidates. Yuhan's near-term focus includes the Phase 2 trial of Lesigercept for allergic diseases, which began recruiting in March 2026. This asset, targeting chronic spontaneous urticaria and other allergic conditions, represents a potential growth driver if data prove positive. The company also benefits from a stable base of approved products, including generics and branded formulations for cardiovascular and metabolic indications. Yuhan's long-standing industry presence and disciplined R&D strategy position it well for sustained growth, though near-term catalysts remain concentrated on pipeline execution.

Upcoming Catalysts (preview)

• H2 2027Lesigercept Phase 2 trial data for allergic diseases50% success